SynBio

New Blue Shift Report From Arthur D. Little Assesses the Future of Synthetic Biology

Retrieved on: 
Thursday, January 18, 2024
Research, Professional Services, Business, Technology, Agriculture, Natural Resources, Genetics, Artificial Intelligence, Science, Chemicals, Plastics, Biotechnology, Health, Manufacturing, Shift, Artificial intelligence, Synthetic biology, Machine learning, Climate change, ADL, SynBio, Safety, Food, Redshift, Growth

Arthur D. Little (ADL) has published The Brave New World Of Synthetic Biology, the latest in a series of leading edge reports from the company’s Blue Shift institute, which explore the impact of new technologies on business, society and people.

Key Points: 
  • Arthur D. Little (ADL) has published The Brave New World Of Synthetic Biology, the latest in a series of leading edge reports from the company’s Blue Shift institute, which explore the impact of new technologies on business, society and people.
  • Synthetic Biology – SynBio for short – is a multi-disciplinary field of innovation focused on the analysis and manipulation of biological systems.
  • SynBio is an extremely diverse field, with the maturity of its technologies ranging from the embryonic to the fully commercialized.
  • Yet while it raises ethical issues, it also presents amazing possibilities across multiple sectors for the furtherance of human development.

Global Synthetic Biology Market Analysis and Forecast to 2028 - Market Harnesses AI, Leads Growth in Asia Pacific, and Offers Novel Healthcare Solutions - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Health, Biotechnology, SynBio, Research, Growth, Synthetic biology, DNA, Knowledge, Global health, CRISPR, Agriculture, Application, Medicine, AI, Ecosystem, User (computing), Environment, Enzyme, COVID-19, Prevalence, Therapy, Boehringer Ingelheim, DSM-IV codes, Pharmaceutical industry

The latest comprehensive analysis of the Global Synthetic Biology Market reveals significant growth and trends that are shaping the industry's future.

Key Points: 
  • The latest comprehensive analysis of the Global Synthetic Biology Market reveals significant growth and trends that are shaping the industry's future.
  • This marks an accelerated growth and reflects the evolving influence of synthetic biology across various sectors.
  • The latest research findings delineate fundamental transformations within the synthetic biology market, shedding light on burgeoning segments, technological progress, and the resultant socio-economic impacts.
  • The industry stands on the cusp of breakout growth, with an ever-deepening commitment to improving global health and environment through synthetic biology innovations.

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results

Retrieved on: 
Friday, November 17, 2023
Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Health Technology, Research, Nanotechnology, Genetics, Science, Carbon, WGS, Twist Bioscience, Telephone, Gene, Twist, SynBio, Investment, Tax, Administration, Martek Biosciences Corporation, PIN, Doctor of Philosophy, Sutro Biopharma, Bayer, Development, Antibody, Growth, NGS, Silicon, ESG, Management, Tobacco, Spice, Video game, Pharmaceutical industry, Agriculture, Vaccine, Library

Revenue: Total revenues for fiscal 2023 grew to $245.1 million compared to $203.6 million for fiscal 2022.

Key Points: 
  • Revenue: Total revenues for fiscal 2023 grew to $245.1 million compared to $203.6 million for fiscal 2022.
  • Cost of Revenues: Cost of revenues for fiscal 2023 grew to $155.4 million compared to $119.3 million for fiscal 2022.
  • Orders: Total orders received for the fourth quarter of fiscal 2023 grew to $71.1 million compared to $62.1 million for the same period of fiscal 2022.
  • Revenue: Total revenues for the fourth quarter of fiscal 2023 grew to $66.9 million compared to $57.3 million for the same period of fiscal 2022.

Pow.Bio Raises $9.5M to Deploy Intelligent Continuous Fermentation Technology to Enable the Future of Biomanufacturing

Retrieved on: 
Wednesday, October 4, 2023
Software, Research, Professional Services, Venture Capital, Technology, Artificial Intelligence, Other Manufacturing, Science, Chemicals, Plastics, Biotechnology, Manufacturing, Health, Hitachi, Food, Emperor, Shannon Hall, Climate Capitalism, Fermentation, Partner (business rank), Vector, Parity, ISelect, Frustration, SynBio, Synthetic biology, Economics, Cryptocurrency, Video game, The Cantos, Bioproduction

Pow.Bio’s goal is to unlock the economic viability of sustainable biomade products by significantly driving down the high costs associated with biomanufacturing.

Key Points: 
  • Pow.Bio’s goal is to unlock the economic viability of sustainable biomade products by significantly driving down the high costs associated with biomanufacturing.
  • The simple fact is that synthetic biology companies today are unable to manufacture products at a price that can displace unsustainable petrochemical or animal derived alternatives.
  • “Early on, we identified continuous fermentation as a necessity to enable cost-competitive, sustainable food production,” said Peter Odemark, co-founder and Managing Partner at Gullspång Re:food.
  • Many in this space blame the challenge of cost effective manufacturing on a lack of commercial scale fermentation capacity.

Twist Bioscience Reports Fiscal Third Quarter 2023 Financial Results

Retrieved on: 
Friday, August 4, 2023
Medical Devices, Hospitals, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Operating cost, DNA, Loss, Twist Bioscience, SG, Doctor of Philosophy, Martek Biosciences Corporation, Telephone, NGS, Calendar, Tax, Cancer Research UK, Accounting standard, GAAP, Research, RNA, Transcriptome, Net, Development, EBITDA, PIN, Investment, Depreciation, Administration, Twist, CMOS, ITF, Medicine, Capital, SynBio, CFO, Growth, Silicon, R, Gene, Congenital hyperinsulinism, Cryptocurrency, Fine chemical, Video game, Spice, Coal, Management, Pharmaceutical industry, Bookkeeping, Uranium mining, Insurance, Textile, Cancer, Library

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2023 ended June 30, 2023.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2023 ended June 30, 2023.
  • Orders: Total orders received for the third quarter of fiscal 2023 were $63.8 million compared to $59.7 million for the same period of fiscal 2022.
  • Shipped products to approximately 2,200 customers in the third quarter of fiscal 2023, versus approximately 1,900 in the third quarter of fiscal 2022.
  • Shipped approximately 171,000 genes during the third quarter of fiscal 2023, compared with approximately 163,000 in the third quarter of fiscal 2022.

Solar Biotech Acquires Noblegen

Retrieved on: 
Tuesday, July 25, 2023
Intellectual property, Research, Fungus, Government, Trent University, Yeast, SynBio, Bacteria, Synthetic biology, Microbiology, Microalgae, Renewable energy

Noblegen will now operate under the name Solar Biotech Canada, continuing as the organization's food-grade-certified (SQF9) biomanufacturing and research & development hub in Canada.

Key Points: 
  • Noblegen will now operate under the name Solar Biotech Canada, continuing as the organization's food-grade-certified (SQF9) biomanufacturing and research & development hub in Canada.
  • "This is a significant step forward for Solar Biotech and its industrial partners since it immediately brings online much-needed capacity and expertise in the biomanufacturing industry.
  • ", said Alex Berlin, CEO of Solar Biotech, and the newly appointed Chairman of Solar Biotech Canada.
  • "At the core of Solar Biotech Canada is the reality that real solutions to real problems can only be achieved through collaboration and joint efforts.

Solar Biotech Acquires Noblegen

Retrieved on: 
Tuesday, July 25, 2023
Intellectual property, Research, Fungus, Government, Trent University, Yeast, SynBio, Bacteria, Synthetic biology, Microbiology, Microalgae, Renewable energy

NORTON, Va. and PETERBOROUGH, ON, July 25, 2023 /PRNewswire/ -- Solar Biotech Inc., a Norton, Virginia-based provider of complete sustainable and scalable biomanufacturing solutions, continues to build out its vertically integrated organization by acquiring Noblegen, an advanced digital biology company based in Peterborough, Ontario, Canada.

Key Points: 
  • Noblegen will now operate under the name Solar Biotech Canada, continuing as the organization's food-grade-certified (SQF9) biomanufacturing and research & development hub in Canada.
  • "This is a significant step forward for Solar Biotech and its industrial partners since it immediately brings online much-needed capacity and expertise in the biomanufacturing industry.
  • ", said Alex Berlin, CEO of Solar Biotech, and the newly appointed Chairman of Solar Biotech Canada.
  • "At the core of Solar Biotech Canada is the reality that real solutions to real problems can only be achieved through collaboration and joint efforts.

Angel Yeast Partners with PhaBuilder to Drive Wider Synthetic Biology Applications with Launch of Joint Venture PHA Factory

Retrieved on: 
Thursday, June 29, 2023
Institute of Botany, Chinese Academy of Sciences, Shanghai Jiao Tong University, Biotechnology, CB Insights, Multimedia, Carbon, US, PHA, Investment, Synthetic biology, Fine chemical, SynBio, Science

In early June, the two partners held a launch ceremony to mark the event and the opening of Hubei's first synthetic biology (SynBio) industrial park.

Key Points: 
  • In early June, the two partners held a launch ceremony to mark the event and the opening of Hubei's first synthetic biology (SynBio) industrial park.
  • Academicians from the Chinese Academy of Sciences, government officials, Angel Yeast, PhaBuilder, and Siemens China executives were all in attendance.
  • In addition to the PHA factory, Angel Yeast has rolled out a strategic plan for SynBio.
  • According to data from CB Insights, the global market size of synthetic biology is projected to reach US$18.9 billion by 2024.

Angel Yeast Partners with PhaBuilder to Drive Wider Synthetic Biology Applications with Launch of Joint Venture PHA Factory

Retrieved on: 
Thursday, June 29, 2023
Institute of Botany, Chinese Academy of Sciences, Shanghai Jiao Tong University, Biotechnology, CB Insights, Carbon, US, PHA, Investment, Synthetic biology, Fine chemical, SynBio, Science

In early June, the two partners held a launch ceremony to mark the event and the opening of Hubei's first synthetic biology (SynBio) industrial park.

Key Points: 
  • In early June, the two partners held a launch ceremony to mark the event and the opening of Hubei's first synthetic biology (SynBio) industrial park.
  • Academicians from the Chinese Academy of Sciences, government officials, Angel Yeast, PhaBuilder, and Siemens China executives were all in attendance.
  • In addition to the PHA factory, Angel Yeast has rolled out a strategic plan for SynBio.
  • According to data from CB Insights, the global market size of synthetic biology is projected to reach US$18.9 billion by 2024.

Angel Yeast Inks Agreements with Hubei Academy of Agricultural Sciences to Boost Agricultural Industrialization

Retrieved on: 
Monday, June 26, 2023
Agricultural science, Farmer, Agriculture, Aquaculture, Food, Fermentation, Research, Multimedia, Vegetable, SynBio, R, Food security, Probiotic, Meat, Synthetic biology, Wine

YICHANG, China, June 26, 2023 /PRNewswire/ -- Angel Yeast (SHA:600298), the world's leading yeast manufacturer, recently inked agreements with Hubei Academy of Agricultural Sciences to conduct research and development initiatives in agricultural microbiology and plant and animal nutrition.

Key Points: 
  • YICHANG, China, June 26, 2023 /PRNewswire/ -- Angel Yeast (SHA:600298), the world's leading yeast manufacturer, recently inked agreements with Hubei Academy of Agricultural Sciences to conduct research and development initiatives in agricultural microbiology and plant and animal nutrition.
  • The two parties will collaborate to fuel agricultural industrialization that will improve efficiency and bring substantial benefits to farmers.
  • Since 2016, beginning with research to set standards and implement evaluations for products, Angel Yeast has carried out a range of cooperation projects with Hubei Academy of Agricultural Sciences.
  • Qin Xianwu, Chief Engineer of Angel Yeast, said, "This collaboration will help Angel Yeast to make solid inroads in the biological agriculture sector while endeavoring to actively integrate into regional, national, and global agricultural development."